Skip to main content
. 2020 Mar 10;20(9):2491–2498. doi: 10.1111/ajt.15822

Table 2.

Summary statistics for high vs low donor‐derived cell‐free DNA (dd‐cfDNA)

Measurement Statistics All patients Low (dd‐cfDNA < 0.5%) High (dd‐cfDNA ≥ 0.5%) P value
dd‐cfDNA measurements a (%) N 79 37 42
Mean (SD) 1.05 (1.267) 0.25 (0.087) 1.76 (1.40)
Median (Q1, Q3) 0.64 (0.21, 1.40) 0.21 (0.19, 0.29) 1.40 (0.87, 2.02)
Min, Max 0.19, 6.70 0.19, 0.49 0.52, 6.70
Change in estimated glomerular filtration rate (eGFR; 3‐6 mo) N 79 37 42 .019 b
Mean (SD) −2.85 (7.526) −0.74 (7.369) −4.74 (7.247)
Median (Q1, Q3) −2.00 (−5.00, 1.00) 0.00 (−3.00, 2.00) −3.50 (−8.00, −1.00)
Min, Max −29.00, 16.00 −29.00, 12.00 −20.00, 16.00
% Change in eGFR (3‐6 mo) N 79 37 42 .004 b
Mean (SD) −4.70 (16.937) −0.40 (18.149) −8.54 (14.98)
Median (Q1, Q3) −3.89 (−9.89, 2.33) 0.00 (−4.92, 4.76) −8.50 (−16.22, −1.39)
Min, Max −70.73, 33.33 −70.73, 33.33 −37.50, 32.65
Presence of donor‐specific antibodies (3‐6 mo) Percentage 18/79 (22.9%) 1/37 (2.7%) 17/42 (40.5%) <.001 c
Recurrent rejection Percentage 9/79 (11.4%) 0/37 (0.0%) 9/42 (21.4%) .003 c
a

0.19 is the numerical value used for dd‐cfDNA measurements denoted by <0.19.

b

Kolmogorov‐Smirnov two‐sample test (high vs low).

c

Fisher's exact test (high vs low).